The launch of the lyophilized powder for injection containing 100 mg of paclitaxel in a single-dose vial for intravenous use follows approval by the FDA on Oct. 8, 2024.

Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first ...

Paclitaxel, the generic version of Taxol, ... Bedford, which has 20 percent of the market for three doses of the drug, expects to release paclitaxel vials into the marketplace soon, ...

The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas ...

Lichtenberg noted that paclitaxel DCBs have progressed with each generation and have fewer issues like cracking or flaking of the drug on the balloon than were seen in the past. “This is bringing us ...

The primary patency rates between sirolimus- and paclitaxel-treated patients at 12 months showed a difference of just 1.2%, with a P value for noninferiority of 0.022, Ulf Teichgräber, MD, (University ...

First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be near-term ...

Sandoz paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the treatment of patients with metastatic breast cancer. The launch of the lyophilized powder for ...

First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be near-term ...